Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CORESTEM, Inc
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Dutch biotech Treeway has completed its Phase I trial of lead program TW001, an oral formulation of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS) and will now prepare for a pivotal Phase III study.
Amid pharma industry’s repeated calls to improve the drug pricing system and properly reflect R&D cost of novel drugs, South Korea released steps that include hiking prices of “global innovative novel drugs” and biomedicines. Response is mixed, with foreign pharmas complaining the steps focus mainly on domestically developed drugs.
Two South Korean bioventures have highlighted positive clinical progress for their gene- and cell-based novel therapies for ALS at the recent ALS/MND International Symposium in Orlando, with ViroMed unveiling the results of a Phase I/II US study for VM202 and Corestem presenting a Phase II study for Neuronata-R, the world's first commercialized stem cell therapy for the debilitating disease.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- CORESTEM, Inc.
- Corestem Inc.